

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4537256

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
MERRIMACK PHARMACEUTICALS, INC.	06/20/2017
RECEIVING PARTY DATA	
Name:	ALPHA CANCER TECHNOLOGIES INC.
Street Address:	101 COLLEGE STREET
Internal Address:	SUITE 200
City:	TORONTO, ONTARIO
State/Country:	CANADA
Postal Code:	M5G 1L7
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	7208576
CORRESPONDENCE DATA	
Fax Number:	(703)519-9802
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(703) 519-9801
Email:	mail@krameramado.com
Correspondent Name:	ANDREAS BALTATZIS
Address Line 1:	330 JOHN CARLYLE STREET
Address Line 2:	KRAMER AMADO P.C.
Address Line 4:	ALEXANDRIA, VIRGINIA 22314
ATTORNEY DOCKET NUMBER:	CLP 3022
NAME OF SUBMITTER:	WENDY K. SPRADLIN
SIGNATURE:	/Wendy K. Spradlin/
DATE SIGNED:	08/04/2017
Total Attachments: 5	
source=EXECUTED_CONFIRMATORY_ASSIGNMENT#page1.tif	
source=EXECUTED_CONFIRMATORY_ASSIGNMENT#page2.tif	
source=EXECUTED_CONFIRMATORY_ASSIGNMENT#page3.tif	
source=EXECUTED_CONFIRMATORY_ASSIGNMENT#page4.tif	

PATENT ASSIGNMENT

WHEREAS, MERRIMACK PHARMACEUTICALS, INC., of One Kendall Square, Suite B7201, Cambridge, Massachusetts 02139 USA, a corporation organized under the laws of Massachusetts ("Assignor") is the sole owner of all right, title and interest in and to the following patents and applications as well as all inventions and technology described thereby (collectively the "Patents"):

- (i) US 5,384,250 titled EXPRESSION AND PURIFICATION OF CLONED ALPHA-FETOPROTEIN;
- (ii) US 6,534,479 titled RECOMBINANT ALPHA-FETOPROTEIN HYBRID CYTOTOXINS FOR TREATING AND DIAGNOSING CANCERS;
- (iii) US 6,416,734 titled RECOMBINANT ALPHA-FETOPROTEIN FOR TREATING AND DIAGNOSING CANCERS;
- (iv) US 6,630,445 titled RECOMBINANT ALPHA-FETOPROTEIN FOR TREATING CANCERS;
- (v) US 6,331,611 titled EXPRESSION AND PURIFICATION OF CLONED HUMAN ALPHA-FETOPROTEIN;
- (vi) US 6,288,034 titled RECOMBINANT HUMAN ALPHA-FETOPROTEIN AS AN IMMUNOSUPPRESSIVE AGENT;
- (vii) US 6,774,108 titled RECOMBINANT HUMAN ALPHA-FETOPROTEIN AS AN IMMUNOSUPPRESSIVE AGENT;
- (viii) US 7,423,024 titled RECOMBINANT HUMAN ALPHA-FETOPROTEIN AS AN IMMUNOSUPPRESSIVE AGENT;
- (ix) US 7,101,837 titled RECOMBINANT HUMAN ALPHA-FETOPROTEIN AS A CELL PROLIFERATIVE AGENT;
- (x) US 7,208,576 titled NON-GLYCOSYLATED HUMAN ALPHA-FETOPROTEIN, METHODS OF PRODUCTION AND USES THEREOF;
- (xi) EP0 749 441 titled EXPRESSION AND PURIFICATION OF CLONED HUMAN ALPHA-FETOPROTEIN;
- (xii) AU 700975 titled RECOMBINANT HUMAN ALPHA FETOPROTEIN AND USES THEREOF;
- (xiii) CN ZL96192764.X titled RECOMBINANT HUMAN ALPHA FETOPROTEIN AND USES THEREOF;
- (xiv) HK 1010153 titled RECOMBINANT HUMAN ALPHA FETOPROTEIN AND USES THEREOF;

- (xv) EP 1 148 779 titled EXPRESSION OF SECRETED HUMAN ALPHA-FETOPROTEIN IN TRANSGENIC ANIMALS (including corresponding national validations in FI, FR, DE, IE, IT, NL, ES, SE, CH, LI, DK, and GB);
- (xvi) CN ZL200480020701.6 titled NON-GLYCOSYLATED HUMAN ALPHA-FETOPROTEIN, METHODS OF PRODUCTION AND USES THEREOF;
- (xvii) CA 2,211,324 titled RECOMBINANT HUMAN ALPHA FETOPROTEIN AND USES THEREOF;
- (xviii) JP H08-523001 titled RECOMBINANT HUMAN ALPHA FETOPROTEIN AND USES THEREOF;
- (xix) JP 2007-243055 titled RECOMBINANT HUMAN ALPHA FETOPROTEIN AND USES THEREOF;
- (xx) CA 2,354,638 titled EXPRESSION OF SECRETED HUMAN ALPHA-FETOPROTEIN IN TRANSGENIC ANIMALS;
- (xxi) JP 2000-592391 titled EXPRESSION OF SECRETED HUMAN ALPHA-FETOPROTEIN IN TRANSGENIC ANIMALS;
- (xxii) US 10/030,351 titled EXPRESSION OF SECRETED HUMAN ALPHA-FETOPROTEIN IN TRANSGENIC ANIMALS;
- (xxiii) AU 2004260129 titled NON-GLYCOSYLATED HUMAN ALPHA-FETOPROTEIN, METHODS OF PRODUCTION AND USES THEREOF;
- (xxiv) BR PI0412803.6 titled NON-GLYCOSYLATED HUMAN ALPHA-FETOPROTEIN, METHODS OF PRODUCTION AND USES THEREOF;
- (xxv) CA 2,526,814 titled NON-GLYCOSYLATED HUMAN ALPHA-FETOPROTEIN, METHODS OF PRODUCTION AND USES THEREOF;
- (xxvi) EP 04778822.9 titled NON-GLYCOSYLATED HUMAN ALPHA-FETOPROTEIN, METHODS OF PRODUCTION AND USES THEREOF;
- (xxvii) IL 172880 titled NON-GLYCOSYLATED HUMAN ALPHA-FETOPROTEIN, METHODS OF PRODUCTION AND USES THEREOF;
- (xxviii) HK 06110039.6 titled NON-GLYCOSYLATED HUMAN ALPHA-FETOPROTEIN, METHODS OF PRODUCTION AND USES THEREOF;
- (xxix) JP 06-521212 titled NON-GLYCOSYLATED HUMAN ALPHA-FETOPROTEIN, METHODS OF PRODUCTION AND USES THEREOF;
- (xxx) KR 2006-7001555 titled NON-GLYCOSYLATED HUMAN ALPHA-FETOPROTEIN, METHODS OF PRODUCTION AND USES THEREOF;

(xxxii) MX 270852 titled NON-GLYCOSYLATED HUMAN ALPHA-FETOPROTEIN,
METHODS OF PRODUCTION AND USES THEREOF; and

(xxxii) All substitutions, extensions, reissues, renewals, divisions, continuations, and continuations-in-part of the above, including all foreign equivalents.

WHEREAS, ALPHA CANCER TECHNOLOGIES INC., of 101 College Street, Suite 200, Toronto, Ontario M5G 1L7 CANADA, a corporation organized under the laws of the Province of Ontario, Canada ("Assignee") desires to acquire all of Assignor's right, title and interest in and to the Patents and the inventions and technology described thereby.

NOW, THEREFORE, in exchange for good and valuable consideration, including the payment of \$10 from Assignee to Assignor, the receipt and sufficiency of which is hereby acknowledged, the parties hereto, intending to be legally bound, agree as follows:

1. Assignor hereby assigns and transfers to Assignee Assignor's entire right, title and interest in and to the Patents, along with the inventions and technology described thereby and all causes of action relating thereto, whether arising before or after the date of this assignment.
2. The Patents, and the inventions and technology described thereby, shall be held and enjoyed by Assignee and its successors and assigns, for its exclusive use and benefit as fully and entirely as the same would have been held and enjoyed by Assignor had this assignment not been made.
3. Assignor hereby authorizes and requests all applicable patent offices throughout the world to issue all letters patent on the Patents and the inventions and technology described thereby to Assignee.
4. Assignor agrees to execute documents, provide information and take actions as reasonably requested by Assignee to confirm the transfer of, register, or enforce the Patents and patent applications transferred under this Patent Assignment.

**THE FOLLOWING TWO PAGES ARE THE SIGNATURE PAGES OF THE ASSIGNOR
AND THE ASSIGNEE**

ASSIGNOR
MERRIMACK PHARMACEUTICALS, INC.

Jeffrey A. Mansie
Signature

June 20, 2017
Date


Jeffrey A. Mansie
Print Name and Title General Counsel

Commonwealth
STATE OF Massachusetts)
COUNTY OF Middlesex) ss.

On this 20th day of June, 2017, before me, the undersigned, a Notary Public in and for the State of Commonwealth of Massachusetts, personally appeared Jeffrey A. Mansie, the party that executed the foregoing instrument and acknowledged the said instrument to be the free and voluntary act and deed of said parties, for the uses and purposes therein mentioned, and on oath stated that he was authorized to execute the said instrument.

IN WITNESS WHEREOF I have hereunto set my hand and official seal this day and year first above written.

B. A. L.
Notary Public in and for the State of _____
residing at _____
Commission Expires: _____



ASSIGNEE
ALPHA CANCER TECHNOLOGIES INC

Signature

Date

Print Name and Title

CITY OF Toronto)
PROVINCE OF Ontario) ss.

On this 6th day of July, 2017, before me, the undersigned, a Notary Public in and for the Province of Ontario, personally appeared Richard Potts, the party that executed the foregoing instrument and acknowledged the said instrument to be the free and voluntary act and deed of said parties, for the uses and purposes therein mentioned, and on oath stated that he was authorized to execute the said instrument.

IN WITNESS WHEREOF I have hereunto set my hand and official seal this day and year first above written.

[Signature]
Notary Public in and for the Province of Ontario
residing at 20 Lansdale Rd, Toronto, ON
Commission Expires: N/A

